Eric Poma, PhD

Chief Executive Officer & Chief Scientific Officer

Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Dr. Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.

Jason Kim

President & Chief Operating Officer

Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Operating Officer. He served as Molecular Templates’ President and Chief Financial Officer from February 2010 to August 2017. Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.

Adam Cutler

Chief Financial Officer

Adam Cutler is a biotechnology executive with over 20 years of experience in equity research, investor relations, capital markets advisory, business development, finance, and management consulting. Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs for Arbutus Biopharma, responsible for designing and executing investor relations programs as well as contributing to the company’s business development and corporate finance efforts. From 2012-2015, he was a Managing Director for The Trout Group LLC and Trout Capital LLC, where he executed financing’s and advised public and private life science companies on investor relations and capital raising strategies. From 2011-2012, he was Director and Senior Biotechnology Analyst for Credit Suisse, where he led the small and mid-cap biotechnology equity research team. From 2007-2011, he was Managing Director and Senior Biotechnology Analyst for Canaccord Genuity. Prior to that, he held Biotechnology Analyst positions at JMP Securities LLC and at Bank of America Merrill Lynch (f/k/a Bank of America Securities). He also worked in healthcare consulting as an Analyst at The Frankel Group and a Consultant for Ernst & Young LLP. He currently serves on the Board of Directors for Inmed Pharmaceuticals. He earned his Bachelor of Arts degree in Economics from Brandeis University.

Barbara Ruskin J.D., Ph.D.

SVP, General Counsel and Chief Patent Officer

Barbara Ruskin J.D., Ph.D. joined Molecular Templates in 2017 as SVP, General Counsel and Chief Patent Officer. She has over 20 years of experience in advising clients in the life sciences industry. From 2015 to 2016, she served as SVP, General Counsel of Bionor Pharma and since May 2012, as President of BA Ruskin Law LLC where she advised biotechnology and pharmaceutical companies in worldwide patent portfolio management, litigation strategies, corporate transactions and due diligence. Prior to May 2012, Barbara was a Partner at the law firm of Ropes & Gray LLP in New York City and an Associate at Fish & Neave LLP. She holds a J.D. from Fordham University School of Law, a Ph.D. in Biochemistry and Molecular Biology from Harvard University, was a post-doctoral Research Fellow at the Whitehead Institute for Biomedical Research at MIT, and holds a B.A. in Biochemistry from the University of California, Berkeley. She is admitted to practice law in New York State and is a registered U.S. patent attorney.

Jack Higgins Ph.D.

SVP of Operations and Head of Manufacturing

Jack Higgins Ph.D. joined Molecular Templates in 2010 and serves as SVP, Operations and Head of Manufacturing and has held numerous leadership positions across Research & Development, Operations, and Manufacturing at Molecular Templates. In his capacity as SVP of Operations and Head of Manufacturing, he provides leadership in areas of GMP manufacturing, supply chain operations, and preclinical product development. Previously, Dr. Higgins’ research efforts at the National Cancer Institute focused on developing therapeutic cancer vaccines and combinational immuno-oncology therapy approaches. He received a BS from Texas A&M University, and holds a PhD and MS from the University of Arkansas.

Erin Willert Ph.D.

SVP of Research & Development

Erin Willert, Ph.D. joined Molecular Templates in 2011 and serves as SVP of Research & Develompent. Previously, Dr. Willert conducted research efforts focused on immune regulation of viral gene expression and biochemical characterization of therapeutic drug targets for parasitic disease, which included the description of a new paradigm for regulation of enzymatic activity in the African trypanosome. Dr. Willert completed her post-doctoral research at the Department of Pathology and Immunology at Washington University School of Medicine. Dr. Willert holds a PhD in Biochemistry from the University of Texas Southwestern Medical Center in Dallas.

Nenad Sarapa M.D.

SVP, Clinical Development

Nenad Sarapa, M.D. M.S. joined Molecular Templates in 2017 as SVP, Clinical Development. He has more than 22 years of experience in clinical research and development of novel oncology, anti-inflammatory and anti-infective agents, including small molecules, monoclonal antibodies, antibody-drug conjugates and antisense oligo therapeutics. Before joining Molecular Templates, beginning in 2013 he was Senior Director of Translational Medicine, Oncology, for Bayer Pharmaceuticals. From 2009 to 2012, Dr. Sarapa was Head of Clinical Pharmacology, Oncology for Hoffman-La Roche. Prior to that, he served as a group manager, project leader and clinical research physician in early clinical development for Johnson & Johnson from 2007 to 2009, Daiichi Sankyo, Inc. from 2005 to 2007, Pfizer, Inc. from 1999-2005, and GlaxoWellcome from 1995 to 1999. Dr. Sarapa earned his MD with a Fellowship in General Medicine and Clinical Pharmacology from the Medical School at the University of Zagreb, Croatia.

Conrad Jordaan

SVP Finance and Corporate Controller

Conrad Jordaan joined Molecular Templates in 2017 as SVP, Finance and Corporate Controller. He has more than 20 years of experience in accounting and finance. Before joining Molecular Templates and since 2014 he was the Corporate Controller at Cytokinetics. Prior to that, from 2011 to 2014 he was the Director, SEC Reporting and Technical Accounting at Onyx Pharmaceuticals. From 2010 to 2011, he was Associate Director, Financial Reporting and Treasury at Savient Pharmaceuticals. Prior to that, he spent 12 years with Ernst & Young in a variety of roles of increasing responsibility, most recently as Senior Manager in New Jersey (2002-2009), and previously in Johannesburg, South Africa (1995-2001); and as Senior Auditor with the National Audit Office in London, United Kingdom (2001-2002). Mr. Jordaan earned an MBA in Finance and Global Business from the Leonard N. Stern School of Business, an Honours Bachelor of Accounting Science from the University of South Africa, and a Baccalaureus Commercii in Accounting from the University of Johannesburg.